Client News

[GlobeNewswire] - NEW YORK -- Ohr Pharmaceutical, Inc. , an ophthalmology research and development company, today reported results for its fiscal year ended September 30, 2014.
Posted: December 22, 2014, 9:01 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: December 22, 2014, 6:22 pm
[PR Newswire] - NEW YORK and PETACH TIKVAH, Israel, Dec. 22, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will ...
Posted: December 22, 2014, 3:45 pm
[at noodls] - - Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis - - Receptos Well Capitalized to Advance Clinical Development Program - SAN DIEGO, ...
Posted: December 22, 2014, 1:11 pm
[GlobeNewswire] - -- Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis --
Posted: December 22, 2014, 1:00 pm
[at noodls] - New Published Data Show Pluristem's PLX Cells Protect Neurons PLX cells could potentially be used to treat stroke or other injuries to the nervous system attributable to low oxygen levels HAIFA, ISRAEL, ...
Posted: December 22, 2014, 8:29 am
[at noodls] - Microsoft Word - 141222_Adocia_ShareholderNewsletter Press Release ADOCIA: Shareholder Newsletter Lyon (France), December 22, 2014 - ADOCIA (Euronext Paris: FR0011184241 - ADOC): shareholder newsletter ...
Posted: December 22, 2014, 8:02 am
[GlobeNewswire] - HAIFA, Israel -- Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, announced today that a study of PLacental eXpanded (PLX) cells was accepted for publication in ...
Posted: December 22, 2014, 8:00 am
Posted: December 19, 2014, 7:29 pm
[GlobeNewswire] - NEW YORK -- Ohr Pharmaceutical, Inc. , a research and development company with a primary focus in ophthalmology, today announced that it will report its financial results for the 2014 fiscal year ended ...
Posted: December 19, 2014, 1:00 pm
Posted: December 19, 2014, 12:16 pm
[CNW Group] - BioAmber Refinances $25 Million Loan
Posted: December 19, 2014, 12:00 pm
[PR Newswire] - MINNEAPOLIS, MN, Dec. 19, 2014 /PRNewswire/ - BioAmber Inc. (BIOA), an industrial biotechnology company producing sustainable chemicals, today announced it has repaid the $25 million loan that it secured in June 2013 and secured a new debt facility with funds managed by Tennenbaum Capital Partners, LLC. The new $25 million term loan has a three-year maturity and an interest-only period that defers principal repayment until at least September 30, 2015. The Company has improved terms with Tennenbaum and the debt facility is expected to free up an additional $12 million of cash through to the end of 2015. BioAmber (BIOA) is an industrial biotechnology company producing sustainable chemicals. Tennenbaum Capital Partners, LLC ("TCP") is a Los Angeles-based alternative investment management firm focused on performing and special situation credit for middle-market companies.
Posted: December 19, 2014, 12:00 pm
[at noodls] - First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing ...
Posted: December 19, 2014, 7:04 am
[at noodls] - Dec 19, 2014 1:30am INDIANAPOLIS and LYON, France , Dec. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing ...
Posted: December 19, 2014, 7:00 am